Theravance IPO Funds Phase III Telavancin Antibiotic Trials
Executive Summary
Theravance plans to use approximately $90 mil. from the proceeds of its initial public offering to fund a Phase III clinical trial program for its lead antibiotic telavancin
You may also be interested in...
Reliant Omacor Launch Funded Through IPO; Launch Set For Late 2005
Reliant Pharmaceuticals will raise cash through an initial public offering to pay for a sales force expansion for the launch of the triglyercide therapy Omacor
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011